Cargando…
Creation of GMP-Compliant iPSCs From Banked Umbilical Cord Blood
Many clinical trials are in progress using cells derived from induced pluripotent stem cells (iPSC) for immunotherapies and regenerative medicine. The success of these new therapies is underpinned by the quality of the cell population used to create the iPSC lines, along with the creation of iPSCs i...
Autores principales: | Tian, Pei, Elefanty, Andrew, Stanley, Edouard G., Durnall, Jennifer C., Thompson, Lachlan H., Elwood, Ngaire J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967326/ https://www.ncbi.nlm.nih.gov/pubmed/35372371 http://dx.doi.org/10.3389/fcell.2022.835321 |
Ejemplares similares
-
Abstract 18 Leveraging the BMDI Cord Blood Bank to Create a GMP-Compliant Cord Blood (CB)–Derived Induced Pluripotent Stem Cell (iPSC) Master Cell Bank (MCB) for Potential Allogeneic Therapies
por: Tian, Pei, et al.
Publicado: (2023) -
MSCs vs. iPSCs: Potential in therapeutic applications
por: Thanaskody, Kalaiselvaan, et al.
Publicado: (2022) -
Pannexin 1 Influences Lineage Specification of Human iPSCs
por: Noort, Rebecca J., et al.
Publicado: (2021) -
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
por: Cichocki, Frank, et al.
Publicado: (2023) -
Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering
por: Gähwiler, Eric K. N., et al.
Publicado: (2021)